<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04763434</url>
  </required_header>
  <id_info>
    <org_study_id>GanSu provincial hospital</org_study_id>
    <nct_id>NCT04763434</nct_id>
  </id_info>
  <brief_title>Dexamethasone and Dexmedetomidine as Adjuvants to Ropivacaine in Ultrasound-guided Multilevel Thoracic Paravertebral Block for Lobectomy: A Prospective, Randomized, Triple-blind Study</brief_title>
  <official_title>Dexamethasone and Dexmedetomidine as Adjuvants to Ropivacaine in Ultrasound-guided Multilevel Thoracic Paravertebral Block for Lobectomy: A Prospective, Randomized, Triple-blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gansu Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gansu Provincial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis is whether perineural dexamethasone and dexmedetomidine prolonged the duration&#xD;
      of analgesia as compared with either perineural dexamethasone or perineural dexmedetomidine&#xD;
      after TPVB.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design: A prospective, randomized, controlled study Setting: Single-center university&#xD;
      hospital. Participants: The study included 90 patients undergoing lobectomy under general&#xD;
      anesthesia.&#xD;
&#xD;
      Interventions: The patients were allocated randomly into the following 3 groups: 20 ml&#xD;
      mixture of 37.5 mg ropivacaine with 5 mg dexamethasone (RS group) or 1 µg/kg dexmedetomidine&#xD;
      (RM group), or with 1 µg/kg dexmedetomidine and 5 mg dexamethasone (RSM group).&#xD;
      Ultrasound-guided TPVB was performed at 4 points-T4-5, T5-6, T6-7, and T7-8 of the surgical&#xD;
      side; 5 mL of solution were injected at each point. Postoperatively, the PCIA was used as&#xD;
      part of multimodal analgesia, and all patients recieve .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 20, 2021</start_date>
  <completion_date type="Anticipated">August 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 20, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the duration of analgesia</measure>
    <time_frame>48 hours after surgery</time_frame>
    <description>time from completion of TPVB operation to VAS more than 3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>total sufentanil consumption</measure>
    <time_frame>48 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS</measure>
    <time_frame>1, 2, 4, 8, 12, 24, 36, and 48 hours after surgery</time_frame>
    <description>VAS at rest and during coughing are evaluated by a blinded observer postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse effects</measure>
    <time_frame>48 hours after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Dexamethasone</condition>
  <condition>Dexmedetomidine</condition>
  <condition>Ropivacaine</condition>
  <condition>Lobectomy</condition>
  <arm_group>
    <arm_group_label>RS group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 ml mixture of 37.5 mg ropivacaine with 5 mg dexamethasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RM group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 ml mixture of 37.5 mg ropivacaine with 1 µg/kg dexmedetomidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RSM group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 ml mixture of 37.5 mg ropivacaine with 1 µg/kg dexmedetomidine and 5 mg dexamethasone (RSM group)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone; dexmedetomidine; ropivacaine</intervention_name>
    <description>Ultrasound-guided multilevelTPVB is performed at the end of lobectomy</description>
    <arm_group_label>RM group</arm_group_label>
    <arm_group_label>RS group</arm_group_label>
    <arm_group_label>RSM group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        ASA physical status I-II grade Undergoing elective lobectomy under general anesthesia.&#xD;
        Participants aged from 16-65 years old.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Refusal for TPVB Inability to obtain informed consent Coagulation disorders, neuropathy, or&#xD;
        body mass index greater than 40 kg/m2 Pregnancy Infections at the site of injection for the&#xD;
        TPVB Allergy to dexamethasone; dexmedetomidine; ropivacaine Clinically significant&#xD;
        cardiovascular, pulmonary, renal, or hepatic diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>wen jun yan, doctor</last_name>
    <phone>17361552758</phone>
    <email>yanwj2008@hotmail.com</email>
  </overall_contact>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 17, 2021</study_first_submitted>
  <study_first_submitted_qc>February 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>February 17, 2021</last_update_submitted>
  <last_update_submitted_qc>February 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gansu Provincial Hospital</investigator_affiliation>
    <investigator_full_name>dong zhang</investigator_full_name>
    <investigator_title>dong zhang</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

